Aligos Therapeutics Inc Total Liabilities
Aligos Therapeutics Inc total liabilities. Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has total liabilities worth $32.77 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ALGS financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aligos Therapeutics Inc (2018–2025)
Total liabilities of Aligos Therapeutics Inc from 2018 to 2025. This chart illustrates how Aligos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Aligos Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Aligos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aligos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Latrobe Magnesium Limited
F:L2Q
|
Germany | €43.84 Million |
|
Archtis Ltd
AU:AR9
|
Australia | AU$15.84 Million |
|
PESTECH International Bhd
KLSE:5219
|
Malaysia | RM1.27 Billion |
|
Damartex
PA:ALDAR
|
France | €371.13 Million |
|
EDM Resources Inc
V:EDM
|
Canada | CA$15.43 Million |
|
Ribbon Acquisition Corp Class A Ordinary Shares
NASDAQ:RIBB
|
USA | $3.03 Million |
|
Pioneer Motor Public Company Limited
BK:PIMO
|
Thailand | ฿255.68 Million |
|
Sung Gang Asset Management Ltd
TWO:6240
|
Taiwan | NT$536.17 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Aligos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Aligos Therapeutics Inc.
Liquidity & Leverage Metrics
Aligos Therapeutics Inc Total Liabilities Ratios Explained
Aligos Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aligos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Aligos Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.99 Million | -64.68% |
| 2024-12-31 | $99.07 Million | +66.65% |
| 2023-12-31 | $59.45 Million | +38.92% |
| 2022-12-31 | $42.79 Million | -15.49% |
| 2021-12-31 | $50.64 Million | +11.88% |
| 2020-12-31 | $45.26 Million | -78.59% |
| 2019-12-31 | $211.41 Million | +74.03% |
| 2018-12-31 | $121.48 Million | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more